Nurix Therapeutics, Inc. is ranked second on the list of 20 Best Biotech Stocks Under $20 to Buy Now. Stifel raised NRIX’s price target to $35 and maintained a Buy rating, highlighting key milestones in 2026. Conversely, Wells Fargo lowered the price target to $29 but still sees potential growth before 2027 catalysts.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) focuses on developing targeted protein modulation therapies using its DELigase platform to address immunology and oncology diseases. The company aims to create precision medicines to improve patient outcomes. While NRIX shows promise, some AI stocks may offer greater upside potential with lower risk.

For those seeking investment opportunities, consider exploring the best short-term AI stock for potential growth. Check out the list of 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now for more options. Disclosure: None.

Read more at Yahoo Finance: Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts